List of Truvada drug patents

Truvada is owned by Gilead.

Truvada contains Emtricitabine; Tenofovir Disoproxil Fumarate.

Truvada has a total of 4 drug patents out of which 0 drug patents have expired.

Truvada was authorised for market use on 02 August, 2004.

Truvada is available in tablet;oral dosage forms.

Truvada can be used as treatment of hiv infection, treatment of hiv; method of treatment of adults infected with hiv-1; treatment of hiv-1 infection in pediatric patients 12 years of age and older.

The generics of Truvada are possible to be released after 13 January, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8592397 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9457036 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US9744181 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

US8716264 GILEAD Compositions and methods for combination antiviral therapy
Jan, 2024

(11 months from now)

Drugs and Companies using EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE ingredient

Market Authorisation Date: 02 August, 2004

Treatment: Treatment of hiv; Method of treatment of adults infected with hiv-1; Treatment of hiv-1 infection in pediatric patients 12 years of age and older; Treatment of hiv infection

Dosage: TABLET;ORAL

How can I launch a generic of TRUVADA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic